The number of hydrogen bonds, and interactive residues of AML inhibitors (Crenolanib, FF-10101, Gilteritinib, KW-2449, PLX3397, Ponatinib, Quizartinib, Sorafenib, Sunitinib, and Tandutinib) with native and mutant (D835A, D835E, D835F, D835G, D835H, D835I, D835N, D835V, and D835Y) FLT3 proteins are depicted in Tables S1–S10, respectively. Here, FLT3 is linked to acute myeloid leukemia.